Cynosure, a US-based medical device company focused on medical aesthetics, has received regulatory clearance from the US Food and Drug Administration (FDA) for its radiofrequency (RF) microneedling device Potenza.
The device is intended for electrocoagulation and haemostasis of soft tissue for dermatologic conditions.
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
Claimed to be only FDA-cleared four-mode RF microneedling device, Potenza allows clinicians to offer patients customised treatments.
The device can be used in monopolar mode and bipolar mode at either 1MHz or 2MHz frequency.
Monopolar RF mode releases energy across a significant area of tissue for deep heating and skin tightening through soft tissue coagulation. Bipolar RF mode provides a concentrated delivery of power to treat superficial tissue to give skin revitalisation results.
The device features Tiger Tip technology, equipped with a single-needle handpiece intended to target and improve blemishes.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataCynosure CEO Todd Tillemans said: “Our goal at Cynosure is to provide our customers with revolutionary technologies so they can consistently deliver outstanding results”
“Potenza takes the microneedling category to a new level by offering unprecedented flexibility for doctors, which translates to personalized treatments and satisfied patients with exceptional outcomes.”
Potenza treatments combine ultrafine needles and radiofrequency energy to penetrate the skin’s top layer and stimulate the body’s natural healing process to regenerate collagen and elastin.
Cynosure claim that the Potenza treatments can perform on all skin types and all body parts.
